Business Description
D. Western Therapeutics Institute Inc
ISIN : JP3548740004
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.4 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 1.04 | |||||
Debt-to-EBITDA | -0.95 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.76 | |||||
Beneish M-Score | -3.3 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1 | |||||
3-Year EBITDA Growth Rate | -40.2 | |||||
3-Year EPS without NRI Growth Rate | -34.7 | |||||
3-Year FCF Growth Rate | -32.5 | |||||
3-Year Book Growth Rate | -18.6 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.27 | |||||
9-Day RSI | 28.16 | |||||
14-Day RSI | 29.43 | |||||
6-1 Month Momentum % | -42.78 | |||||
12-1 Month Momentum % | -58.47 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.2 | |||||
Quick Ratio | 11.65 | |||||
Cash Ratio | 8.97 | |||||
Days Inventory | 906.35 | |||||
Days Sales Outstanding | 111.48 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | -2.69 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 91.32 | |||||
Operating Margin % | -229.31 | |||||
Net Margin % | -233.63 | |||||
FCF Margin % | -136.37 | |||||
ROE % | -68.24 | |||||
ROA % | -40.48 | |||||
ROIC % | -212.89 | |||||
ROC (Joel Greenblatt) % | -484.12 | |||||
ROCE % | -43.77 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 6.52 | |||||
PB Ratio | 3.02 | |||||
Price-to-Tangible-Book | 3.34 | |||||
EV-to-EBIT | -2.43 | |||||
EV-to-EBITDA | -2.43 | |||||
EV-to-Revenue | 5.72 | |||||
EV-to-FCF | -4.17 | |||||
Price-to-Median-PS-Value | 0.19 | |||||
Price-to-Net-Current-Asset-Value | 3.95 | |||||
Price-to-Net-Cash | 14.47 | |||||
Earnings Yield (Greenblatt) % | -41.12 | |||||
FCF Yield % | -20.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
D. Western Therapeutics Institute Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2.81 | ||
EPS (TTM) (€) | -0.204 | ||
Beta | 0.79 | ||
Volatility % | 33.65 | ||
14-Day RSI | 29.43 | ||
14-Day ATR (€) | 0.015603 | ||
20-Day SMA (€) | 0.5136 | ||
12-1 Month Momentum % | -58.47 | ||
52-Week Range (€) | 0.408 - 1.33 | ||
Shares Outstanding (Mil) | 32.28 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
D. Western Therapeutics Institute Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
D. Western Therapeutics Institute Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
D. Western Therapeutics Institute Inc Frequently Asked Questions
What is D. Western Therapeutics Institute Inc(FRA:6DW)'s stock price today?
When is next earnings date of D. Western Therapeutics Institute Inc(FRA:6DW)?
Does D. Western Therapeutics Institute Inc(FRA:6DW) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |